Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04759326

Neurorehabilitation Through Hippotherapy of a Brain Stroke

Cerebrovascular accident [CVA] (medical term for stroke) is a high burden worldwide disorder and the second leading cause of disability. As illustrated by the number of survivors that remain disabled after a CVA (2 out of 3 according to the US National Stroke Association), recovery is limited, and novel neurorehabilitation approaches are urgently needed. Hippotherapy is an emerging specialized rehabilitation approach, performed by accredited health professionals on a specially trained horse via its movement. A body of scientific evidence has gradually emerged in recent years, showing robust benefits of hippotherapy in various massive neurological disabling conditions including brain stroke.

The aim of the study is to analyze the effect of a hippotherapy program of several cycles delivered during 22 weeks in total, on the functional and global evolution of post-stroke patients (with a score of Rankin ≥ 3 at inclusion) during the outpatient rehabilitation phase. A second purpose is to measure the impact of the intervention on the quality of life of their close caregivers.

A prospective clinical trial on the effectiveness of hippotherapy versus conventional outpatient rehabilitation alone will be carried out. The 22-weeks program includes three cycles of hippotherapy as follows: an initial 2-weeks cycle, an intermediate 1-week cycle and a final 1-week cycle. One-hour daily sessions will be conducted during each cycle exclusive additional rehabilitation care. After each cycle, the patients will have a 9-weeks rest period where they will continue their conventional therapy. A battery of clinical tests will measure both functional and psychological outcome. The primary end point will be the functional independence of the patient. The secondary end points will consider the patient's sensorimotor and cognitive function, the severity of stroke and the quality of life, as well as the caregivers' burden and quality of life.

Program evaluation is important in neurorehabilitation to ensure that patients are achieving meaningful outcomes from the care. A primary question is how do stroke patients clinically evolve after being discharged from the hospital and how stable is the achieved rehabilitation outcome. Hippotherapy optimizes brain plasticity and has a strong impact on the global rehabilitation process and functional outcome of these patients. A remaining question concerns the improvement of the caregivers' quality of life.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Equiphoria

La Canourgue, 48500, France

Location status: Recruiting

Location contact

Carole Imbernon, MD

SUB_INVESTIGATOR

Didier Smadja, MD, PhD

PRINCIPAL_INVESTIGATOR

Djibril Soumah, MD

SUB_INVESTIGATOR

Emmanuelle Dos-Santos, PhD

SUB_INVESTIGATOR

Florent Lepilliet, MD

SUB_INVESTIGATOR

Hélène Viruega, ESMHL

CONTACT

[email protected]

Isabelle Favre-Wiki, MD

PRINCIPAL_INVESTIGATOR

Katia Garambois, MD

SUB_INVESTIGATOR

Loïc Legris, MD

SUB_INVESTIGATOR

Magdalena Voicu, MD

SUB_INVESTIGATOR

Manuel Gaviria, MD, PhD

CONTACT

[email protected]

Manvel Aghasaryan, MD

SUB_INVESTIGATOR

Mohamed Reda Belabed, MD

PRINCIPAL_INVESTIGATOR

Nicolas Chausson, MD, PhD

SUB_INVESTIGATOR

Olivier Detante, MD, PhD

SUB_INVESTIGATOR

Pauline Cuisenier, MD

SUB_INVESTIGATOR

Thibault Lalu, MD

SUB_INVESTIGATOR

Tony Al Tarcha, MD

SUB_INVESTIGATOR

Yassine Boukriche, MD

SUB_INVESTIGATOR

About this study

According to the WHO (2016), almost 1.1 million of Europeans suffer a stroke each year (17 million worldwide), which adds to a pool of 33 million stroke survivors. The case fatality rates are about 15% by 1 month, 25% by 1 year, and 50% by 5 years. Over one third of survivors are left disabled (modified Rankin Scale score 3-5) 5 years after stroke due to physical, cognitive, and/or emotional deficits. These deficiencies are often addressed in the hospital's acute care and/or during inpatient rehabilitation. Much of the scientific efforts to date have focused on medical programs involving acute care and hospital-based inpatient rehabilitation. However, many patients continue to experience difficulties beyond this period of recovery and long-term disability often occurs. In such cases, dealing with impairment is frequently ineffective, and when it is beneficial, the functional bases for recovery are mainly unclear.

Stroke is a brutal event in the course of a lifetime. It is a break in reality affecting the body and the psyche, not only for the individual but also for the family. It disrupts the many foundations that a person has built over the course of his or her life. Acceptance of the disease, medical care and its effects on daily life, global impairment, limitation of activity and restriction of participation, are a set of factors that the psyche cannot integrate at once. Following this event, the person and their caregivers must take the time to accept and rebuild themselves. A new sense of temporality is an essential factor in the management of a post-stroke patient and a question that must be addressed by the caregiver.

A body of scientific evidence has gradually emerged in recent years, reflecting the benefits of hippotherapy in various disabling neurological conditions. During hippotherapy, specific execution and repetition of a task are key elements of learning/strengthening/promoting a function and a robust backbone of neurorehabilitation through neural plasticity mechanisms. Hippotherapy is therefore slowly emerging as a cutting-edge method of neurorehabilitation. The post-injury experience is a powerful modulator of functional recovery following neurological disorders. Our method of hippotherapy has powerful effects on brain plasticity and neurological outcome. Beneficial results have been observed in a wide variety of brain disorders and include sensorimotor enhancement, cognitive enhancement, mental well-being, and delayed disease progression. Such an environment most likely promotes the synthesis of different neuroactive substances (e.g., BDNF, norepinephrine, acetylcholine, dopamine, serotonin), which reflect the level of arousal, motivation, attention, affection and emotion of a subject or directly drive the action (e.g., glutamate, or GABA). These endogenous molecules are strongly involved in the induction and maintenance of synaptic plasticity, namely long-lasting stable molecular, anatomical and functional modifications.

In this randomized interventional study, the effectiveness of neurological rehabilitation by hippotherapy will be studied and its scope compared in terms of functional recovery, autonomy and quality of life. Stroke patients will be included and treated from the end of the inpatient rehabilitation phase (starting 3-6 months post-stroke). They will be compared to a control group of patients undergoing conventional outpatient rehabilitation. Both groups will undergo the same qualitative and quantitative clinical tests. We will also compare the quality of life of the respective caregivers before and after the end of the program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old
  • Ischemic or haemorrhagic stroke according to ICD 10 I61-I69 (30)
  • Inclusion > 3 months post-stroke
  • Deficit still existing (Rankin score ≥ 3 and ≤ 4 at inclusion)
  • Existing declaration of informed consent
  • Affiliation of the patient to a social security scheme
  • Minimal abduction of the hip of 25 degrees bilateral with no history of hip dislocation and/or dysplasia
  • Certificate of non-contraindication issued by the referring physician

Exclusion criteria

  • Major cognitive impairment affecting comprehension (Mini Mental State Examination test < 24 points)
  • Global or sensory aphasia
  • Neurological or psychiatric co-morbidity (other than mild-to-moderate post-stroke depression)
  • Evidence of an uncontrolled seizure disorder
  • Substance abuse
  • History of uncontrolled pain
  • History of allergic reactions to dust and/or horsehair, or severe asthma
  • Overweight (≥ 110 kg)
  • Contraindications to physical activity
  • Inability or medical contraindication to travel to the Equiphoria Institute by personal car or taxi
  • History of horse riding or hippotherapy care during the last 6 months
  • Pregnant or lactating women
  • Patients participating in other biomedical research or in a period of exclusion

Treatment and study plan

hippotherapy

Other

Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.

Conventional Neurorehabilitation

Other

The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.

Primary outcomes

  1. For the patient: Change in Functional Independence Measure (FIM)

    Time frame: Change from baseline to week 22; change from week 22 to week 48

    FIM is an 18-item of physical, psychological and social function. The tool is used to assess a patient's level of disability as well as change in patient status in response to rehabilitation or medical intervention. Tasks that are evaluated using the FIM include bowel and bladder control, transfers, locomotion, communication, social cognition as well as the following six self-care activities: Feeding, Grooming, Bathing, Upper Body Dressing, Lower Body Dressing, Toileting. Each item on the FIM is scored on a 7-point Likert scale, and the score indicates the amount of assistance required to perform each item (1 = total assistance in all areas, 7 = total independence in all areas). A final summed score is created and ranges from 18 - 126, where 18 represents complete dependence/total assistance and 126 represents complete independence.

Secondary outcomes

  1. For the patient: Change in Modified Rankin Scale (MRS)

    Time frame: Change from baseline to week 22; change from week 22 to week 48

    MRS is a standardized measure that describes the extent of disability after a stroke. The MRS is a single item scale. It ranges from 0 (no symptoms) to 6 (death due to stroke).

  2. For the patient: Change in Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA)

    Time frame: Change from baseline to week 22

    FMA is a stroke-specific, performance-based impairment index designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. The scale is comprised of five domains: Motor functioning (in the upper and lower extremities), Sensory functioning (evaluates light touch on two surfaces of the arm and leg, and position sense for 8 joints), Balance (contains 7 tests, 3 seated and 4 standing), Joint range of motion (8 joints), Joint pain. Assessment items are scored on the basis of ability to complete the item using a 3-point ordinal scale where 0 = cannot accomplish; 1 = partially accomplished; and 2 = completely accomplished (0-35 = Very severe; 36-55 = Severe; 56-79 = Moderate; > 79 = Light). The total possible result for the evaluation is 226 points.

  3. For the patient: Change in Berg Balance Scale (BBS)

    Time frame: Change from baseline to week 22

    BBS was developed for use with community-dwelling elderly individuals. It can also be used in patients with stroke. It is a 14-item scale where patients must maintain positions and complete moving tasks of varying difficulty. In most items, patients must maintain a given position for a specified time. Patients receive a score from 0-4 on their ability to meet these balance dimensions. A global score can be calculated out of 56. A score of 0 represents an inability to complete the item, and a score of 56 represents the ability to independently complete the item.

  4. For the patient: Change in Displacement of the Centre of Pressure (COP) while sitting through a force pad

    Time frame: Change from baseline to week 22

    Assessment of the displacement of COP during dynamic sitting on the horse simulator (TESS©) equipped with saddle pressure sensors. This measurement allows to assess the postural balance improvement. A trained observer records the sequence.

  5. For the patient: Change in Walking distance in two minutes (2-MWT)

    Time frame: Change from baseline to week 22

    2-MWT is a functional walking test in which the distance that a client can walk within two minutes is evaluated. This test has been used to assess individuals with stroke. It is a valid measure of self-selected walking speed and the most time efficient walking test (compared to 6-MWT and 12-MWT). Distance walked, and the number and duration of rests during the 2 minutes should be measured. Scores range from 0 meters or feet for patients who are non-ambulatory to the maximum biological limits for normal healthy individuals.

  6. For the patient: Changes in the Short Form Health Survey (SF-36) for quality

    Time frame: Change from baseline to week 22; change from week 22 to week 48

    SF-36 is a 36-item questionnaire which measures Quality of Life (QoL) across eight domains. The eight domains that the SF36 measures are as follows: physical functioning; role limitations due to physical health; role limitations due to emotional problems; energy/fatigue; emotional well-being; social functioning; pain; general health. A single item is also included that identifies perceived change in health, making the SF-36 a useful indicator for change in QoL over time and treatment. The recommended scoring system for the SF-36 is a weighted Likert system for each item. Items within subscales are totalled to provide a summed score for each subscale or dimension. Each of the 8 summed scores is linearly transformed onto a scale from 0 (negative health) to 100 (positive health) to provide a score for each subscale.

  7. For the caregiver: Change in Zarit Burden Inventory (ZBI)

    Time frame: Change from baseline to week 22

    ZBI is one of the most commonly used instruments to assess caregiving burden in clinical and research settings. The revised version contains 22 items. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). The higher the score, the more extensive the burden. It can be self-administered or administered by a third party without training.

  8. For the caregiver: Changes in the Short Form Health Survey (SF-36) for quality of life

    Time frame: Change from baseline to week 22

    SF-36 is a 36-item questionnaire which measures Quality of Life (QoL) across eight

Study contacts

Contact information is provided by the study sponsor or research team.

Didier Smadja, MD, PhD

CONTACT

[email protected]

Manuel Gaviria, MD, PhD

CONTACT

[email protected]

+33466321046

Sponsors and collaborators

Lead sponsor

Alliance Equiphoria

Other

Collaborators

  • Boehringer Ingelheim
  • Centre Hospitalier Sud Francilien
  • Centre Hospitalier de Béziers
  • University Hospital, Grenoble

Registry information

Official study title

Neurorehabilitation Through Hippotherapy on Neurofunctional Sequels of Brain Stroke: (i) Effect on Patient's Functional Independence, Sensorimotor and Cognitive Capacities and Quality of Life (ii) Effect on Caregivers' Quality of Life

Acronym: HippoPostCVA

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Feb 18, 2021
Registry last updated
Jul 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.